The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR)
Abstract
Background: Pulmonary hypertension (PH) results in severely impaired quality of life (QoL) in people with this condition. The CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the only questionnaire providing a disease-specific measurement of symptoms, functioning and QoL in PH patients. It has already been adapted for use in several countries. The aim of this study was to adapt and validate CAMPHOR for the Polish-speaking population.
Methods: Two panels (bilingual and lay) were conducted to translate CAMPHOR into Polish. This new version was then tested by cognitive debriefing interviews with 15 patients. Finally, a postal validation survey was conducted with 56 patients on two occasions 2 weeks apart to assess its psychometric properties.
Results: No problems were experienced in producing a Polish translation of CAMPHOR. Interviewees responded well to the Polish CAMPHOR, finding it relevant, comprehensible and easy to complete. For all three CAMPHOR scales (Symptoms, Activity, QoL), The Cronbach alpha coefficients were above 0.8 at both time points, indicating high internal consistency. Test-retest reliability for the three scales achieved a value above 0.80. Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of CAMPHOR scales. The Polish CAMPHOR could distinguish between patients who differed according to their perceived general health and perceived disease severity. No significant differences in scores were found between participants grouped by gender or age.
Conclusions: The Polish version of CAMPHOR demonstrated good psychometric properties and is recommended for use in clinical practice.
Keywords: adaptationCAMPHORquality of lifepatient reported outcomepulmonary hypertension
References
- Kurzyna M. Epidemiologia i leczenie nadciśnienia płucnego w Polsce AD 2015 [Epidemiology and treatment of pulmonary hypertension in Poland AD 2015], 2015. http://www ptkardio pl/pobierz_zalacznik/c4a8e1fa1c5a26bffccc06dd2dcad139.
- McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl): S97–107.
- Jaïs X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(25): 2127–2134.
- Simonneau G, Rubin LJ, Galiè N, et al. PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008; 149(8): 521–530.
- Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117(23): 3010–3019.
- Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22): 2894–2903.
- Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347(5): 322–329.
- Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334(5): 296–301.
- Doward LC, McKenna SP. Defining patient-reported outcomes. Value Health. 2004; 7 Suppl 1: S4–S8.
- Gilbert C, Brown MCJ, Cappelleri JC, et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest. 2009; 135(1): 137–142.
- McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010; 55(18): 1915–1922.
- Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6): 800–804.
- Chen H, De Marco T, Kobashigawa EA, et al. Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J. 2011; 38(3): 608–616.
- Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J. 2006; 28(4): 808–815.
- McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006; 15(1): 103–115.
- Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy. 1992; 22(3): 307–319.
- Meads DM, McKenna SP, Doughty N, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J. 2008; 32(6): 1513–1519.
- Gomberg-Maitland M, Thenappan T, Rizvi K, et al. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant. 2008; 27(1): 124–130.
- Coffin D, Duval K, Martel S, et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008; 15(2): 77–83.
- Ganderton L, Jenkins S, McKenna SP, et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011; 16(8): 1235–1240.
- Selimovic N, Rundqvist B, Kjörk E, et al. Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden. Scand J Public Health. 2012; 40(8): 777–783.
- Cima K, Twiss J, Speich R, et al. The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes. 2012; 10: 110.
- Reis A, Twiss J, Vicente M, et al. Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire. Health Qual Life Outcomes. 2016; 14(1): 110.
- Wapenaar M, Twiss J, Wagenaar M, et al. Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands. Neth Heart J. 2016; 24(6): 417–424.
- Aguirre-Camacho A, Stepanous J, Blanco-Donoso LM, et al. Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain. Rev Esp Cardiol (Engl Ed). 2017; 70(6): 467–473.
- Hunt S, Alonso J, Bucquet D, et al. Cross-cultural adaptation of health measures. Health Policy. 1991; 19(1): 33–44.
- Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015; 37(1): 67–119.
- Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985; 35(273): 185–188.
- Hagell P, Hedin PJ, Meads DM, et al. Effects of method of translation of patient-reported health outcome questionnaires: a randomized study of the translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden. Value Health. 2010; 13(4): 424–430.
- McKenna SP, Wilburn J, Twiss J, et al. Adaptation of the QoL-AGHDA scale for adults with growth hormone deficiency in four Slavic languages. Health Qual Life Outcomes. 2011; 9: 60.
- Matura LA, McDonough A, Carroll DL. Symptom prevalence, symptom severity, and health-related quality of life among young, middle, and older adults with pulmonary arterial hypertension. Am J Hosp Palliat Care. 2016; 33(3): 214–221.
